10-K Decoder · All companies

Voyager Therapeutics, Inc.

VYGR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$40.4M$80.0M−49.5%
Operating income−$132M−$83.3M−58.3%
Net income−$120M−$65.0M−84.2%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$4.00M$13.4M−70.1%
Operating income−$26.4M−$30.6M+13.7%
Net income−$24.7M−$27.9M+11.5%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Voyager Therapeutics's revenue in FY2025?
$40.4M in FY2025 (Fiscal year ended Dec 31, 2025), −49.5% vs $80.0M a year earlier, per its 10-K filed Mar 2026.
Was Voyager Therapeutics profitable in FY2025?
No: net income was −$120M and operating income −$132M in FY2025.
What was Voyager Therapeutics's revenue in Q3 2026?
$4.00M (−70.1% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.